VIDEO: ANXV shows early positive results in treatment of retinal vein occlusion

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Anders Haegerstrand, MD, PhD, and Anna Frostegård, MD, PhD, of Annexin Pharmaceuticals discuss a phase 2a trial of ANXV for the treatment of retinal vein occlusion.

“We achieved our main goals for the study,” Frostegård said. “We see that ANXV is well tolerated and safe, and we also see signals of effect, also making it clear that we differentiate ourselves from anti-VEGF.”

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures:
Frostegård reports being chief scientific and chief medical officer of Annexin Pharmaceuticals. Haegerstrand reports being CEO of Annexin Pharmaceuticals.

Read more about

This post was originally published on this site